nach oben

Current Hypertension Reports

Erschienen in:

01.07.2014 | Hypertension and the Kidney (R Carey, Section Editor)

The Protective Arms of the Renin-Angiontensin System in Stroke

verfasst von: Claudia A. McCarthy, Lachlan J. Facey, Robert E. Widdop

Erschienen in: Current Hypertension Reports | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

It is quite well established that activation of the so-called protective arms of the renin-angiotensin system (RAS), involving both AT₂ and Mas receptors, provides a counter-regulatory role to AT₁ receptor overactivity that may drive pathological changes in the cardiovascular system. In this brief review, we will focus on recent evidence that identifies at least three different pathways that may be effective in the setting of stroke and may be complementary with AT₁ receptor blockade. Such mechanisms include AT₂ receptor stimulation, Mas receptor stimulation and insulin-regulated aminopeptidase blockade. This report highlights recent data demonstrating striking neuroprotective effects in preclinical models of stroke targeting each of these pathways, which may pave the way for translational opportunities in this field.

Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612–23.PubMedCrossRef

Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, et al. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke. 2012;7:407–18.PubMedCrossRef

Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55:207–13.PubMedCentralPubMedCrossRef

Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803.PubMedCrossRef

Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT₁ receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke. 1999;20:2391–9.

Groth W, Blume A, Golhlke P, Unger T, Culman J. Chronic pretreatment with candersartan improves recovery from focal cerebral ischemia in rats. J Hypertens. 2003;21:2175–82.PubMedCrossRef

Ito T, Yamakawa H, Bregonzio C, Terron J, Falcon-Neri A, et al. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT₁ receptor antagonist. Stroke. 2002;33:2297–303.

Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, et al. Angiotensin AT₂ receptor protects against cerebral ischemia-induced neuronal Injury. FASEB J. 2005;19:617–9.

Lu Q, Zhu YZ. Wong PTH Neuroprotective effect of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport. 2005;16:1963–7.PubMedCrossRef

10.

Mecca AP, O’Connor TE, Katovich MJ, Sumners C. Candersartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp Physiol. 2009;94:937–46.PubMedCentralPubMedCrossRef

11.

Nishimura Y, Ito T, Saavedra J. Angiotensin II AT₁ blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31:2478–86.

12.

Walther T, Olah L, Harms C, Maul B, Bader M, et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J. 2002;16:169–76.PubMedCrossRef

13.

Brdon J, Kaiser S, Hagemann F, Zhao Y, Culman J, et al. Comparison between early and delayed systemic treatment with candesartan of rats after ischemic stroke. J Hypertens. 2007;25:187–96.PubMedCrossRef

14.

Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurological outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab. 2004;24:467–74.PubMedCrossRef

15.

Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRef

16.

Schrader J, Luders S, Kulischewski A. Morbidity and mortality after stroke eprosartan compared with nitrendipine for secondary prevention (MOSES) trial. Stroke. 2005;36:1218–24.PubMedCrossRef

17.

Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept. 1998;78:1–11.PubMedCrossRef

18.

Achard J, Fournier A, Mazouz H, Caride V, Penar P, et al. Protection against ischemia: a physiological function of the renin-angiotensin system. Biochem Pharmacol. 2001;62:261–71.PubMedCrossRef

19.

Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT₁ receptor antagonist in the brain. Cell Mole Neurobiol. 2006;26:1099–111.

20.

Thone-Reineke C, Zimmermann M, Neumann C, Krikov M, Gerova N, et al. Are angiotensin receptor blockers neuroprotective. Curr Hypertens Rep. 2004;6:257–66.PubMedCrossRef

21.

Widdop R, Jones E, Hannan R, Gaspari T. Angiotensin AT₂ receptors: cardiovascular hope or hype? B J Pharmacol. 2003;140:809–24.

22.

Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT₂ receptors in the developing rat fetus. J Clin Invest. 1991;88:921–33.

23.

Yu L, Zheng M, Wang W, Rozanski GJ, Zucker IH. Developmental changes in AT₁ and AT₂ receptor-protein expression in rats. J Renin Angiotensin Aldosterone Syst. 2010;11:214–21.

24.

Chao J, Yang L, Buch S, Gao L. Angiotensin II increased neuronal stem cell proliferation: role of AT₂R. PLoS One. 2013;8:63488.

25.

Luo CX, Jin X, Cao CC, Zhu MM, Wang B, et al. Bidirectional regulation of neurogenesis by neuronal nitric oxide synthase derived from neurons and neural stem cells. Stem Cells. 2010;28:2041–52.PubMedCrossRef

26.

Aimone JB, Wiles J, Gage FH. Potential role for adult neurogenesis in the encoding of time in new memories. Nat Neurosci. 2006;9:723–7.PubMedCrossRef

27.

Kempermann G, Wiskott L, Gage FH. Functional significance of adult neurogenesis. Curr Opin Neurobiol. 2004;14:186–91.PubMedCrossRef

28.

Maul B, von Bohlen und Halbach O, Becker A, Sterner-Kock A, Voigt JP, et al. Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. J Mol Med. 2008;86:563–71.PubMedCrossRef

29.

Reinecke K, Lucius R, Reinecke A, Rickert U, Herdengen T, et al. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: Role of the AT₂ receptor and the transcription factor NF-kB. FASEB J. 2003;17:2094–6.

30.

Lucius R, Gallinat S, Rosenstiel P, Unger T, Sievers J. The angiotensin II type 2 receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med. 1998;188:661–70.PubMedCentralPubMedCrossRef

31.••

Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, et al. AT₂-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis. 2013;51:177–91. First direct evidence that AT ₂ R stimulation can evoke the release of neurotrophic factors such as BDNF.

32.

Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT₂ receptor and tissue injury: therapeutic implications. Curr Hypertens Rep. 2014;16:416–26.

33.

Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens. 2008;26:544–52.PubMedCrossRef

34.

Kishi T, Hirooka Y, Sunagawa K. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats. J Cardiol. 2012;60:489–94.PubMedCrossRef

35.

Li JM, Mogi M, Tsukuda K, Tomochika H, Iwanami J, et al. Angiotensin II induced neural differenciation via angiotensin II type 2 (AT₂) receptor- MMS2 cascade involving interaction between AT₂ receptor-interacting protein and scr homology 2 domain containing protein tyrosine phosphatase 1. Mole Endocrinol. 2007;21:499–511.

36.

Horiuchi M, Mogi M, Iwai M. The angiotensin II type 2 receptor in the brain. J Renin Angiotensin Aldosterone Syst. 2010;11:1–6.PubMedCrossRef

37.

Iwai M, Liu HW, Chen R, Ide A, Okamoto S, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation. 2004;110:843–8.PubMedCrossRef

38.

Mogi M, Li MH, Iwanami J, Min LJ, Tsukuda K, et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension. 2006;48:141–8.PubMedCrossRef

39.••

McCarthy CA, Vinh A, Callaway JC, Widdop RE. AT₂R stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40:1482–9. The first proof of principal study that direct AT ₂ R is stroke protective.

40.•

McCarthy C, Vinh A, Broughton B, Sobey CG, Callaway J, et al. Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension. 2012;60:1531–7. The first report that direct AT ₂ R stimulation after stroke reduces the severity of brain damage.

41.

Lee S, Brait VH, Arumugam TV, Evans MA, Kim HA, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012;4:16–25.PubMedCentralPubMedCrossRef

42.

Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, et al. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291–9.PubMedCrossRef

43.

Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523–32.PubMedCrossRef

44.••

Joseph JP, Mecca AP, Regenhardt RW, Bennion DM, Rodriguez V, et al. The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacol. 2014;81:134–41. The first study to demonstrate stroke protection with C21 in normotensive rats.CrossRef

45.••

McCarthy C, Vinh A, Miller AA, Hallberg A, Alterman M, et al. Direct angiotensin AT₂ receptor stimulation using a novel AT₂ receptor agonist, Compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One. 2014;9(4):e95762. First report that treatment with C21, even up to 6 hours after stroke, is protective in conscious hypertensive rats.

46.••

Min LJ, Mogi M, Tsukuda K, Jing F, Ohshima K, et al. Direct Stimulation of Angiotensin II Type 2 Receptor Initiated After Stroke Ameliorates Ischemic Brain Damage. Am J Hypertens. 2014, Feb 26 [Epub ahead of print]. First study to demonstrate stroke protection with C21 in mice.

47.

Vincent JM, Kwan YW, Chan SL, Perrin-Sarrado C, Atkinson J, et al. Constrictor and dilator effects of angiotensin II on cerebral arterioles. Stroke. 2005;36:2692–5.CrossRef

48.

Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010;55:924–31.PubMedCrossRef

49.

Zhao Y, Foryst-Ludwig A, Bruemmer D, Culman J, Bader M, et al. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem. 2005;94:1395–401.PubMedCrossRef

50.

Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, et al. Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol. 2013;40:580–8.PubMedCrossRef

51.

Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, et al. Angiotensin II AT₁ receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011;36:857–70.

52.

McCarthy CA, Widdop RE, Deliyanti D, Wilkinson-Berka JL. Brain and retinal microglia in health and disease: an unrecognized target of the renin-angiotensin system. Clin Exp Pharmacol Physiol. 2013;40:571–9.PubMedCrossRef

53.

Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.PubMedCrossRef

54.

Iwanami J, Mogi M, Tsukuda K, Min L, Sakata A. Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice. Stroke. 2008;39:2554–9.PubMedCrossRef

55.

Iwanami J, Mogi M, Tsukuda K, Min L, Sakata A, et al. Effect of angiotensin II type 2 receptor deletion in hematopoietic cells on brain ischemia- reperfusion injury. Hypertension. 2011;58:404–9.PubMedCrossRef

56.

Chen J, Zhao Y, Chen S, Wang J, Xiao X, et al. Neuronal over-expression of ACE2 protects brain from ischemia-induced damage. Neuropharmacology. 2014;79C:550–8.CrossRef

57.

Lu J, Jiang T, Wu L, Gao L, Wang Y, et al. The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides. 2013;47:289–95.PubMedCrossRef

58.•

Mecca AP, Regenhardt RW, O’Connor TE, Joseph JP, Raizada MK, et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084–96. First report that that Ang 1-7 is beneficial in the context of stroke.PubMedCentralPubMed

59.••

Regenhardt RW, Mecca AP, Desland F, Ritucci-Chinni PF, Ludin JA, et al. Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats. Exp Physiol. 2014;99:442–53. First demonstration that Ang 1-7 is protective in a chronic model of stroke.PubMedCrossRef

60.

Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol. 2003;284:H1985–94.PubMed

61.

Feterik K, Smith L, Katusic ZS. Angiotensin-(1-7) causes endothelium-dependent relaxation in canine middle cerebral artery. Brain Res. 2000;873:75–82.PubMedCrossRef

62.

Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, et al. Relative affinity of angiotensin peptides and novel ligands at AT₁ and AT₂ receptors. Clin Sci (Lond). 2011;121:297–303.

63.

Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216:R1–R17.PubMedCrossRef

64.

Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol. 2011;300:R804–17.PubMedCentralPubMedCrossRef

65.

Becker LK, Etelvino GM, Walther T, Santos RA, Campagnole-Santos MJ. Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am J Physiol Heart Circ Physiol. 2007;293:H1416–24.PubMedCrossRef

66.

Regenhardt RW, Bennion DM, Sumners C. Cerebroprotective action of angiotensin peptides in stroke. Clin Sci (Lond). 2014;126:195–205.CrossRef

67.

Regenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, et al. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology. 2013;71:154–63.PubMedCrossRef

68.

Jiang T, Gao L, Shi J, Lu J, Wang Y, et al. Angiotensin-(1-7) modulates renin-angiotensin system associated with reducing oxidative stress and attenuating neuronal apoptosis in the brain of hypertensive rats. Pharmacol Res. 2013;67:84–93.PubMedCrossRef

69.

Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960–6.PubMedCrossRef

70.

Keller SR, Scott HM, Mastick CC, Aebersold R, Lienhard GE. Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem. 1995;270:23612–8.PubMedCrossRef

71.

Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001;276:48623–6.PubMedCrossRef

72.

Fernando RN, Albiston AL, Chai SY. The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus–potential role in modulation of glucose uptake in neurones? Eur J Neurosci. 2008;28:588–98.PubMedCrossRef

73.

Faure S, Chapot R, Tallet D, Javellaud J, Achard JM, et al. Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J Physiol Pharmacol. 2006;57:329–42.PubMed

74.••

Pham V, Albiston AL, Downes CE, Wong CH, Diwakarla S, et al. Insulin-regulated aminopeptidase deficiency provides protection against ischemic stroke in mice. J Neurotrauma. 2012;29:1243–8. Proof of principal study showing that inhibition of IRAP signalling reduces stroke damage.PubMedCrossRef

75.

Andersson H, Hallberg M. Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers. Int J Hypertens. 2012;789671:18.

Titel: The Protective Arms of the Renin-Angiontensin System in Stroke
verfasst von: Claudia A. McCarthy
Lachlan J. Facey
Robert E. Widdop
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 7/2014
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-014-0440-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Cardiac Target Organ Damage in Hypertension: Insights from Epidemiology

ACE Overexpression in Myelomonocytic Cells: Effect on a Mouse Model of Alzheimer’s Disease

Prevalence of Metabolic Syndrome and Obesity-Associated Hypertension in the Racial Ethnic Minorities of the United States

Around-the-clock Ambulatory Blood Pressure Monitoring is Required to Properly Diagnose Resistant Hypertension and Assess Associated Vascular Risk

Individualizing Antihypertensive Combination Therapies: Clinical and Hemodynamic Considerations